The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium
Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
Read More- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -
- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -
- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne -
Read MorePrivate Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies
US$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headache
Lobe creates Cynaptec Pharmaceuticals, Inc. which will own and develop Conjugated Psilocin TM
Plans to conduct consumer and safety testing during second quarter 2025
Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production
Single dose pre-workout supplement expected to be available in at least three flavors and launch in specialty retailers of nutritional products in 2025
Read More
Survey of 1,672 healthcare providers and 200 healthcare consumers reveals aligned and divergent perspectives on digital tools, engagement barriers, and strategies driving success in 2025
Read More84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously
Read More
"MMJ BioPharma Cultivation is engaged not only in a fight for justice but for the integrity of our legal system. As we stand against the DEA's disregard for Supreme Court directives, we are not merely defending our rights; we are upholding the principle that the DEA should not be above the law, especially not one that regulates medical progress. This isn't just our battle-it's a stand for every American whose life and liberties depend on the fair application of justice." - Duane Boise, CEO of MMJ BioPharma Cultivation
Read MoreOne clinical trial site activated
Patient enrollment expected in April
Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product
Aspire anticipates releasing initial clinical data from trial at the end of the second quarter
Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product
Duane Boise CEO of MMJ International Holdings stated, “When private citizens or companies fall short of compliance, the DEA acts swiftly and decisively. The question is, why is there no comparable urgency when the failure comes from within the DEA's own ranks? The agency's silence on this matter is not just a public relations problem—it's a breach of public trust."
Read More
The new shampoo combines natural ingredients and a patented Biomimetic Cuticle Technology in a formula that is scientifically proven to repair damaged hair and make it easier than ever to detangle, smooth and style.
Read More
Black Book's ad hoc survey of 200 healthcare executives reveals real-time disruptions, cost inflation, and stalled innovation as Trump-era tariffs expand across key healthcare imports.
Read More
Gelclair® is the company's third commercialized prescription product
Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force
Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients
Read MoreTransaction Expected to Help TRNR Generate More than $65M in 2025 Revenue on a Pro Forma basis
Wattbike is the Leading, Indoor-Bike Brand for Elite-Athlete Training and is Used by Olympians and Professional Sports Teams Worldwide - Including the NFL, NBA, MLB, NHL and Premier League
TRNR Listing, Global Distribution Network to Help Wattbike Accelerate Growth, Especially in Key Markets Like US and Germany; Wattbike's Deep Penetration into Leading UK Gyms and Expanding D2C Customer Base to Similarly Speed Up Step-Changes to TRNR Top and Bottom Lines
Transaction Delivers on Previously-Announced LOI, Combines Highly Complementary Businesses to Create a Scaled, International Operation Anchored in the US, Germany and UK, the #1, #2 and #3 Fitness Markets Globally
Deal - Expected to be TRNR's 3rd Within a Year-and-a-Half - Builds on its Transformative Portfolio Strategy for Creating Long-Term Shareholder Value
Acquisition Expected to Close as Early as the Second Quarter of 2025, Subject to Standard Regulatory Requirements
Read More
